A Phase 2/3 interventional study of Oral Nutrition Supplement and Tube Feed in Pediatric Cancer, Nutrition Related Cancer and Nutrition Aspect of Cancer, sponsored by Corey Hawes. Completed at 1 site in United States. Open to participants aged 2 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Corey Hawes · Phase 2/3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Nearly 60% of pediatric patients diagnosed with cancer develop malnutrition caused by a combination of disease burden, side effects of chemotherapy, and the intensity of cancer treatment. These patients are known to have an increased risk of infection, treatment-related toxicity, inferior clinical outcomes, and increased risk of mortality. Malnutrition may progress to cancer cachexia, characterized by anorexia, increased inflammation, decreased fat, and decreased muscle mass with subsequent weight loss, which is associated with decreased overall survival.
The goal of the proposed research is to determine changes in body composition, weight status, and nutritional status between common nutrition interventions including oral nutrition supplements (ONS), appetite stimulants, and enteral nutrition (EN) among pediatric cancer patients. A secondary goal of this research is to utilize the findings to develop clinical nutrition guidelines for this patient population. The specific objective of the research proposed is to solve the lack of evidence to adequately treat nutritional deficits in the pediatric oncology population. Without this data, there is a lack of clinical consistency in the initiation and selection of appropriate nutrition interventions to provide a more definitive pathway of care. This study can help formulate a clinical guideline for this patient population before, during, and after treatment.
The investigators plan to enroll a minimum of 45 subjects between the ages of 2-18 years old, over the course of one year, including males and females of all ethnicities. The subject will be a newly diagnosed pediatric patient with cancer who will actively receive chemotherapy at UK Healthcare's Kentucky Children's Hospital (KCH).
All those who enroll will have a baseline ultrasound and biomarkers taken at enrollment. Participants will also receive 'standard of care' medical nutrition therapy (MNT) counseling at diagnosis for following a high protein/high-calorie diet. If any of the enrolled participants lose >10% of the diagnosis weight, the participants will then be randomized to receive (1) oral nutrition supplements, (2) age-appropriate appetite stimulants, or (3) enteral nutrition via a feeding tube. At the point of randomization, participants will receive another ultrasound and biomarkers. Those randomized will then receive additional ultrasounds and biomarkers at 1 month and 3 months after randomization. The remaining patients that have either weight maintenance or weight gain, will be utilized as a comparator group and will receive an ultrasound at 3 months and 6 months from enrollment/diagnosis. Each group will have a goal of at least 10 patients per group.
Those receiving ONS will be prescribed a standard ONS (1.0 kcal per mL) that will meet a minimum of 50% of estimated energy needs to promote weight gain but allow for continued regular dietary intakes. The ONS will be prescribed as 8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. Those receiving age-appropriate appetite stimulants will be provided either cyproheptadine or olanzapine. Subjects will be given cyproheptadine if the participants fall between the ages of 2-12 years of age and olanzapine if the participants are >12 years of age or older. Table 1 summarizes the medication dosage forms, initial and dose titration options, and precautions/contraindications of each appetite stimulant. Medication adjustments will be made within 2-4 weeks of initiation due to the variable peak effect times, and chemotherapy treatment plans dictating clinic follow-up. Those randomized to EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs to allow for continued regular dietary intakes during the day. After placement of a feeding tube, an abdominal x-ray will be obtained per hospital policy to confirm the appropriate placement of the feeding tube prior to use to ensure the safety of using said feeding tube.
Baseline demographics will be collected, including gender, age, diagnosis, QMLT ultrasound measurement, subjective global assessment (SGA) malnutrition risk, pediatric z-scores, and activity levels. Investigators will assess the subjects' nutritional intake, body composition via QMLT ultrasound, mid-upper arm circumference, pediatric z-scores (weight, length, and body mass index), biomarkers (leptin, IL-6, Lipid profiles, Cystatin-C, Vitamin D, and C-reactive protein), compliance and tolerance to nutrition intervention, physical activity, and clinical outcomes (rates of infection, number of hospital days for non-chemotherapy administration, number of clinic visits for non-chemotherapy administration, chemotherapy toxicity CTCAE grade, rate or relapse, and 1-year survival rates) at multiple time points throughout the study. Nutritional assessment will involve a 24-hour food recall which will be performed at diagnosis, randomization, and then every 1-2 weeks once randomized to an intervention. Weight loss and pediatric z-scores (weight-for-age, length-for-age, and BMI-for-age) will be assessed every 1-2 weeks throughout the study enrollment. Ultrasound assessment will be of the QMLT by measuring at the midpoint between the ASIS and the upper pole of the patella. The measurements will be taken bilaterally, three times, and averaged together for the final measurement. Ultrasound assessment will occur at enrollment when weight loss criteria are met for randomization, and then at 1 month and 3 months after randomization (or when the weight lost is regained).
Pediatric physical activity will be assessed every 1-2 weeks in combination with ultrasound measurements. Adherence and adverse effects to medications, tube feeds, or oral nutrition supplements will be assessed at each clinic visit. Biomarkers will be analyzed at randomization, 1 month, and 3 months after randomization.
Standard of care for patients are to receive MNT education at diagnosis. For those that lose weight, standard of care is to receive the nutrition interventions listed above (oral nutrition supplements, appetite stimulants, or enteral nutrition via feeding tube). The standard of care is to generally go from a least invasive to a more invasive approach. The research components of this study include being randomized to a nutrition intervention rather than a non-validated step-wise approach, the ultrasound measurements, and the biomarkers. These components are not considered standard of care and are research procedures. Baseline demographics will be collected, including gender, age, diagnosis, QMLT ultrasound measurement, subjective global assessment (SGA) malnutrition risk, pediatric z-scores, and activity levels. The team will assess the subjects' nutritional intake, body composition via QMLT ultrasound, mid-upper arm circumference, pediatric z-scores (weight, length, and body mass index), biomarkers (leptin, IL-6, Lipid profiles, Cystatin-C, Vitamin D, and C-reactive protein), compliance and tolerance to nutrition intervention, physical activity, and clinical outcomes (rates of infection, number of hospital days for non-chemotherapy administration, number of clinic visits for non-chemotherapy administration, chemotherapy toxicity CTCAE grade, rate or relapse, and 1-year survival rates) at multiple timepoints throughout the study. Nutritional assessment will involve a 24-hour food recall which will be performed at diagnosis, randomization, and then every 1-2 weeks once randomized to an intervention. Weight loss and pediatric z-scores (weight-for-age, length-for-age, and BMI-for-age) will be assessed every 1-2 weeks throughout the study enrollment. Ultrasound assessment will be of the QMLT by measuring at the midpoint between the ASIS and the upper pole of the patella, a total of 4 ultrasounds will be conducted during the study. The measurements will be taken bilaterally, three times, and averaged together for the final measurement. Ultrasound assessment will occur at enrollment when weight loss criteria are met for randomization, and then every 1-2 weeks for up to 8 weeks after randomization. Pediatric physical activity will be assessed every 1-2 weeks in combination with ultrasound measurements. Adherence and adverse effects to medications, tube feeds, or oral nutrition supplements will be assessed at each clinic visit.
Biomarkers will be analyzed at randomization, and weeks 4 and 8 after randomization. Additionally, measurements of resource utilization will be measured such as the number of hospital days for non-chemotherapy-related problems, the number of sick visits to the clinic, dietitian visits, infections, and rates of relapse or overall survival. Biomarkers will be drawn when the children are in the clinic for chemotherapy or lab work. The participants will already have their central venous line accessed by a qualified clinic RN and labs will be drawn at that time to ensure no extra harm to the patient. Additionally, all patients will have EMLA cream used to numb the area prior to having a clinic RN who is trained in accessing ports and has accessed the ports during previous clinic visits and will continue to do so throughout therapy.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 20 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →This is the only study on the registry with Corey Hawes as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard of Care who have either weight gain, weight maintenance, or weight loss \<10%.
Other: Standard of Care
Those receiving ONS will be prescribed a standard ONS (1.0 kcal per mL) that will meet a minimum of 50% of estimated energy needs to promote weight gain but allow for continued regular dietary intakes. The ONS will be prescribed as 8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs.
Dietary Supplement: Oral Nutrition Supplement
Those randomized to EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs to allow for continued regular dietary intakes during the day.
Dietary Supplement: Tube Feed
Those receiving age-appropriate appetite stimulants will be provided either cyproheptadine or olanzapine. Subjects will be given cyproheptadine if they fall between the ages of 2-12 years of age and olanzapine if they are \>12 years of age or older.
Drug: Cyproheptadine · Drug: Olanzapine
8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day
Diet education on high protein, high calorie food consumption
Body Composition
Change in quadriceps muscle layer thickness is measured by ultrasound and reported as change from baseline in centimeters.
Time frame: Baseline, at 3 and 6 months after baseline
Change in Body Composition Mid-Upper Arm
Change in body composition will be measured by mid-upper arm circumference and will be measured in centimeters.
Time frame: Baseline, at 3 and 6 months after baseline
Participants With Intervention Intolerances
Intervention intolerances were assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) to determine toxicity grade.
Time frame: Randomization through end of treatment (6 months)
Change in Weight
Weight will be measured in kilograms (kg).
Time frame: Baseline, at 3 and 6 months after baseline
Change in Body Mass Index (BMI)
Body Mass Index (BMI) will be calculated using weight in pounds (lb) and height in inches (in).
Time frame: Baseline, at 3 and 6 months after baseline
Change in Biomarker IL-6
IL-6 concentrations were measured from blood samples collected via central venous lines.
Time frame: Baseline, at 3 and 6 months after baseline
Change in Biomarker Leptin
Leptin concentrations were measured from blood samples collected via central venous lines.
Time frame: Baseline, at 3 and 6 months after baseline
Change in Total Cholesterol
Total cholesterol concentrations were measured from blood samples collected via central venous lines.
Time frame: Baseline, at 3 and 6 months after baseline
Change in Cystatin-C
Cystatin-C concentrations were measured from blood samples collected from blood samples collected via central venous lines.
Time frame: Baseline, at 3 and 6 months after baseline
Change in Physical Activity
Physical activity was assessed using the Lanksy Play-Performance Scale, a measure of Pediatric Functional Status based on parent descriptions of the child's activity and response to treatment. Scores ranges from 0-100, with higher scores indicating greater physical activity and functional status. Results are reported as the change from baseline to each follow-up assessment.
Time frame: Baseline, at 3 and 6 months after baseline
Tube Feeding Compliance
Tube feeding compliance was assessed weekly by comparing the self-reported tube feeding volume (mL) with the prescribed tube feeding volume (mL). Results are reported as the change in volume relative to the prescribed amount.
Time frame: From randomization through 3 months after randomization
Oral Nutrition Supplements Compliance
Compliance with prescribed oral nutrition supplements was assessed based on the amount of oral nutrition supplement (ONS) consumed compared with the prescribed amount. ONS was prescribed as 8 oz per dose at least once daily, depending on estimated nutrient needs. Percent compliance represents the amount of ONS consumed relative to the prescribed amount over the assessment period.
Time frame: From randomization through 3 months after randomization
Percentage of Participants Who Were Medication Compliant
Medication compliance will be analyzed by self-reported weekly medication use during the period from randomization through 3 months after randomization. Overall compliance for the 3-month period will be calculated based on the number of days prescribed medications were taken as directed compared with the number of days medications were taken less than prescribed.
Time frame: From randomization through 3 months after randomization
Days Hospitalized for Nutrition-Related Issues
The total number of days hospitalized for nutrition-related issues during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.
Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Number of Clinic Visits for Nutrition-Related Issues
The total number of clinic visits for nutrition-related issues during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.
Time frame: Baseline through 6 months for control group. From randomization through 3 months for intervention groups.
Number of Participants With Malnutrition Diagnosis
The number of participants with a malnutrition diagnosis during the assessment period, as documented in the study assessment. The data table reports the number of participants with a malnutrition diagnosis (yes responses).
Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Number of Participants With Relapse or Disease Progression
The number of participants with relapse or disease progression during the assessment period. The data table reports the number of participants with relapse or disease progression (yes responses).
Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Number of Days That Cancer Treatment is Put on Hold
The total number of days that cancer treatment was put on hold during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.
Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
CTCAE Toxicity Grade
Treatment-related toxicities were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale (Grades 1-4). Higher grades indicate more severe toxicity. All participants were assessed for treatment-related toxicities during the assessment period. No participants experienced treatment-related toxicities.
Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Cancer Diagnosis Type
These measurements will include the diagnosis type (cancer type).
Time frame: Baseline through 6 months for control group. Randomization through 3 months for intervention group.
Biomarker Vitamin D Level
Vitamin D levels (ng/mL) will be measured from blood samples collected via central venous lines at each study assessment.
Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Triglyceride Level
Triglyceride levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.
Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Biomarker: Low-Density Lipoprotein (LDL) Level
Low Density Lipoprotein (LDL) levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.
Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Biomarker: High-Density Lipoprotein (HDL) Level
High-Density Lipoprotein (HDL) levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.
Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
Biomarker: C-Reactive Protein (CRP) Level
C-Reactive Protein (CRP) Level (mg/L) will be measured via central venous lines at each study assessment.
Time frame: Baseline to 3 Months and Baseline to 6 Months (End of Treatment)
| Milestone | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Started | 17 | 1 | 0 | 2 |
| Completed | 15 | 1 | 0 | 1 |
| Not completed | 2 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 |
| Withdrew: Change in medical management | 1 | 0 | 0 | 0 |
Change in quadriceps muscle layer thickness is measured by ultrasound and reported as change from baseline in centimeters.
| Centimeters | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Mean Baseline to 3 Months | -0.12596 ± 1.0417 | -0.5450 | — | -0.6750 |
| Mean Baseline to 6 Months (End of Treatment) | -0.46722 ± 0.89758 | 0.185 | — | -0.290 |
Change in body composition will be measured by mid-upper arm circumference and will be measured in centimeters.
| Centimeters | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | -0.352 ± 0.285 | 0 | — | -0.30 |
| Baseline to 6 Months (End of Treatment) | -0.605 ± 0.392 | 0.91 | — | 1.29 |
Intervention intolerances were assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) to determine toxicity grade.
| Participants | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Participants With Intervention Intolerances | 0 | 0 | 0 | 0 |
Weight will be measured in kilograms (kg).
| Kilograms | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | -2.991 ± 1.378 | -4.1 | — | -1.29 |
| Baseline to 6 Months (End of Treatment) | -4.782 ± 1.207 | 8.8 | — | 2.7 |
Body Mass Index (BMI) will be calculated using weight in pounds (lb) and height in inches (in).
| lbs/inches^2 | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | -1.064 ± 0.526 | -1.6 | — | -1.93 |
| Baseline to 6 Months (End of Treatment) | -1.982 ± 0.378 | 1.8 | — | 4.3 |
IL-6 concentrations were measured from blood samples collected via central venous lines.
| pg/mL | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | -8.119 ± 6.260 | -0.5 | — | 39.71 |
| Baseline to 6 Months (End of Treatment) | -5.856 ± 7.764 | -0.9 | — | 0 |
Leptin concentrations were measured from blood samples collected via central venous lines.
| ng/mL | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | 0.66 ± 0.446 | 1.66 | — | 2.09 |
| Baseline to 6 Months (End of Treatment) | -0.644 ± 0.431 | 0.74 | — | 1.01 |
Total cholesterol concentrations were measured from blood samples collected via central venous lines.
| mg/dL | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | 51.125 ± 14.168 | -3.0 | — | 24.0 |
| Baseline to 6 Months (End of Treatment) | 51.750 ± 11.750 | 2.0 | — | -1.0 |
Cystatin-C concentrations were measured from blood samples collected from blood samples collected via central venous lines.
| mg/L | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | -1.030 ± 3.15 | 1.18 | — | 114.57 |
| Baseline to 6 Months | -0.980 ± 2.111 | 7.06 | — | -5.75 |
Physical activity was assessed using the Lanksy Play-Performance Scale, a measure of Pediatric Functional Status based on parent descriptions of the child's activity and response to treatment. Scores ranges from 0-100, with higher scores indicating greater physical activity and functional status. Results are reported as the change from baseline to each follow-up assessment.
| score on a scale | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | 5.445 ± 2.073 | -30 | — | 0 |
| Baseline to 6 Months (End of Treatment) | 3.636 ± 1.521 | -10 | — | 0 |
Tube feeding compliance was assessed weekly by comparing the self-reported tube feeding volume (mL) with the prescribed tube feeding volume (mL). Results are reported as the change in volume relative to the prescribed amount.
| Participants | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Tube Feeding Compliance | 0 | 0 | — | 0 |
Compliance with prescribed oral nutrition supplements was assessed based on the amount of oral nutrition supplement (ONS) consumed compared with the prescribed amount. ONS was prescribed as 8 oz per dose at least once daily, depending on estimated nutrient needs. Percent compliance represents the amount of ONS consumed relative to the prescribed amount over the assessment period.
| Percentage of Prescribed ONS Consumed | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Oral Nutrition Supplements Compliance | 0 (0 to 0) | 90 (90 to 90) | — | 0 (0 to 0) |
Medication compliance will be analyzed by self-reported weekly medication use during the period from randomization through 3 months after randomization. Overall compliance for the 3-month period will be calculated based on the number of days prescribed medications were taken as directed compared with the number of days medications were taken less than prescribed.
| percentage of participants | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Percentage of Participants Who Were Medication Compliant | 0 | 0 | — | 100 |
The total number of days hospitalized for nutrition-related issues during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.
| Days | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Days Hospitalized for Nutrition-Related Issues | 0.54 ± 1.941 | 0 ± 0 | — | 0 ± 0 |
The total number of clinic visits for nutrition-related issues during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.
| Clinic Visits | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Number of Clinic Visits for Nutrition-Related Issues | 1 ± 3.606 | 16 | — | 21 |
The number of participants with a malnutrition diagnosis during the assessment period, as documented in the study assessment. The data table reports the number of participants with a malnutrition diagnosis (yes responses).
| Participants | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Number of Participants With Malnutrition Diagnosis | 1 | 1 | 0 | 1 |
The number of participants with relapse or disease progression during the assessment period. The data table reports the number of participants with relapse or disease progression (yes responses).
| Participants | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Number of Participants With Relapse or Disease Progression | 0 | 0 | — | 0 |
The total number of days that cancer treatment was put on hold during the assessment period, as determined by review of the participant's medical record for hospitalizations related to nutritional status or nutrition-related complications.
| Days | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Number of Days That Cancer Treatment is Put on Hold | 16.38 ± 26.225 | 14 | — | 7 |
Treatment-related toxicities were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale (Grades 1-4). Higher grades indicate more severe toxicity. All participants were assessed for treatment-related toxicities during the assessment period. No participants experienced treatment-related toxicities.
| participants | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| CTCAE Toxicity Grade | 0 | 0 | — | 0 |
These measurements will include the diagnosis type (cancer type).
| Participants | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Hodgkin's Lymphoma | 2 | 0 | 0 | 0 |
| T-Cell ALL | 1 | 0 | 0 | 0 |
| B-Cell ALL | 4 | 0 | 0 | 0 |
| CNS Tumor | 2 | 0 | 0 | 0 |
| Wilm's Tumor | 2 | 0 | 0 | 0 |
| Acute Myeloid Leukemia | 3 | 0 | 0 | 0 |
| Ewing's Sarcoma | 1 | 0 | 0 | 0 |
| Non-Hodgkin's Lymphoma | 0 | 1 | 0 | 0 |
| Hepatoblastoma | 0 | 0 | 0 | 1 |
Vitamin D levels (ng/mL) will be measured from blood samples collected via central venous lines at each study assessment.
| ng/mL | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | -0.975 ± 2.192 | -5.5 | — | -10.5 |
| Baseline to 6 Months (End of Treatment) | -1.088 ± 2.308 | 26.3 | — | 4.0 |
Triglyceride levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.
| mg/dL | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | 93.125 ± 46.523 | 6.0 | — | -10.0 |
| Baseline to 6 Months (End of Treatment) | 155.125 ± 23.775 | 13.0 | — | 115.0 |
Low Density Lipoprotein (LDL) levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.
| mg/dL | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | 43.125 ± 12.803 | 8.0 | — | 30.0 |
| Baseline to 6 Months (End of Treatment) | 39.875 ± 11.470 | 10 | — | -10 |
High-Density Lipoprotein (HDL) levels (mg/dL) will be measured from blood samples collected via central venous lines at each study assessment.
| mg/dL | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | -9.0 ± 7.464 | -3.0 | — | -4.0 |
| Baseline to 6 Months (End of Treatment) | -15.00 ± 5.898 | -1.0 | — | -9.0 |
C-Reactive Protein (CRP) Level (mg/L) will be measured via central venous lines at each study assessment.
| mg/L | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants |
|---|---|---|---|---|
| Baseline to 3 Months | -2.530 ± 3.083 | 4.52 | — | -6.59 |
| Baseline to 6 Months (End of Treatment) | -3.356 ± 2.581 | 6.07 | — | -4.69 |
Collected over 6 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Oral Nutrition Supplements | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Enteral Nutrition | — | — | — |
| Appetite Stimulants | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
There were no participants enrolled in the Enteral Nutrition Arm. Participants were randomized at study enrollment. Oral Nutrition Supplements, Enteral Nutrition, and Appetite Stimulants represent protocol-defined nutrition interventions that were implemented after randomization only if participants met prespecified clinical criteria (\>10% weight loss/insufficient energy intake). No participants were enrolled directly into these intervention groups.
| Age, Continuous(years) | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants | Total |
|---|---|---|---|---|---|
| Mean | 10.15 ± 4.616 | 8 | — | 12 | 9.82 ± 4.246 |
| Sex: Female, Male(Participants) | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants | Total |
|---|---|---|---|---|---|
| Female | 5 | 1 | — | 1 | 7 |
| Male | 10 | 0 | — | 0 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | — | 0 | 0 |
| Not Hispanic or Latino | 15 | 1 | — | 1 | 17 |
| Unknown or Not Reported | 0 | 0 | — | 0 | 0 |
| Race (NIH/OMB)(Participants) | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | — | 0 | 0 |
| Asian | 0 | 0 | — | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | — | 0 | 0 |
| Black or African American | 1 | 0 | — | 0 | 1 |
| White | 14 | 1 | — | 1 | 16 |
| More than one race | 0 | 0 | — | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | — | 0 | 0 |
| Region of Enrollment(participants) | Control | Oral Nutrition Supplements | Enteral Nutrition | Appetite Stimulants | Total |
|---|---|---|---|---|---|
| United States | 15 | 1 | — | 1 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2024 to primary completion in Aug 2025, 18 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 47 phase 2/3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 90. This study's 18 months is below that.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyproheptadine · Olanzapine